skip to main content
語言:
顯示結果: 查詢種類 顯示結果: 查詢種類 索引

Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification

Ginghina, Octav ; Hudita, Ariana ; Zamfir, Marius ; Spanu, Andrada ; Mardare, Mara ; Bondoc, Irina ; Buburuzan, Laura ; Georgescu, Sergiu Emil ; Costache, Marieta ; Negrei, Carolina ; Nitipir, Cornelia ; Galateanu, Bianca

Frontiers in oncology, 2022-03, Vol.12, p.856575 [同儕審閱期刊]

可取得全文

引用 被引用
  • 題名:
    Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification
  • 著者: Ginghina, Octav ; Hudita, Ariana ; Zamfir, Marius ; Spanu, Andrada ; Mardare, Mara ; Bondoc, Irina ; Buburuzan, Laura ; Georgescu, Sergiu Emil ; Costache, Marieta ; Negrei, Carolina ; Nitipir, Cornelia ; Galateanu, Bianca
  • 主題: artificial intelligence ; colorectal cancer ; liquid biopsy ; Oncology ; patients stratification ; robotic surgery
  • 所屬期刊: Frontiers in oncology, 2022-03, Vol.12, p.856575
  • 描述: Colorectal cancer (CRC) is the second most frequently diagnosed type of cancer and a major worldwide public health concern. Despite the global efforts in the development of modern therapeutic strategies, CRC prognosis is strongly correlated with the stage of the disease at diagnosis. Early detection of CRC has a huge impact in decreasing mortality while pre-lesion detection significantly reduces the incidence of the pathology. Even though the management of CRC patients is based on robust diagnostic methods such as serum tumor markers analysis, colonoscopy, histopathological analysis of tumor tissue, and imaging methods (computer tomography or magnetic resonance), these strategies still have many limitations and do not fully satisfy clinical needs due to their lack of sensitivity and/or specificity. Therefore, improvements of the current practice would substantially impact the management of CRC patients. In this view, liquid biopsy is a promising approach that could help clinicians screen for disease, stratify patients to the best treatment, and monitor treatment response and resistance mechanisms in the tumor in a regular and minimally invasive manner. Liquid biopsies allow the detection and analysis of different tumor-derived circulating markers such as cell-free nucleic acids (cfNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in the bloodstream. The major advantage of this approach is its ability to trace and monitor the molecular profile of the patient's tumor and to predict personalized treatment in real-time. On the other hand, the prospective use of artificial intelligence (AI) in medicine holds great promise in oncology, for the diagnosis, treatment, and prognosis prediction of disease. AI has two main branches in the medical field: (i) a virtual branch that includes medical imaging, clinical assisted diagnosis, and treatment, as well as drug research, and (ii) a physical branch that includes surgical robots. This review summarizes findings relevant to liquid biopsy and AI in CRC for better management and stratification of CRC patients.
  • 出版者: Switzerland: Frontiers Media S.A
  • 語言: 英文
  • 識別號: ISSN: 2234-943X
    EISSN: 2234-943X
    DOI: 10.3389/fonc.2022.856575
    PMID: 35356214
  • 資源來源: DOAJ Directory of Open Access Journals
連結
返回到檢索清單
    臺南大學版權所有 © 2016 NUTN All Rights Reserved

正在檢索遠程資料庫，請稍等